Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 5:57 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 25 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Germline BRCA1 Gene Mutation Clear all
Active, not recruiting Phase 3 Interventional Accepts healthy volunteers

Studying the Effect of Denosumab on Preventing Breast Cancer in Women With a BRCA1 Germline Mutation

NCT04711109
View directory record Official record
Conditions
BRCA1 Mutation, Breast Cancer, Breast Diseases, Breast Neoplasms, Breast Carcinoma, Neoplasms
Interventions
Denosumab, Placebo, Quality-of-Life Assessment
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
25 Years to 55 Years · Female only
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2033
U.S. locations
47
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 38 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2025 · Synced Jul 22, 2026, 5:57 AM EDT
Terminated Phase 2 Interventional Results available

Maintenance Rucaparib in BRCA1, BRCA2 or PALB2 Mutated Pancreatic Cancer That Has Not Progressed on Platinum-based Therapy

NCT03140670
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
RUCAPARIB
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 27, 2023 · Synced Jul 22, 2026, 5:57 AM EDT
Active, not recruiting Phase 2 Interventional

Talazoparib in Treating Patients With Recurrent, Refractory, Advanced, or Metastatic Cancers and Alterations in the BRCA Genes

NCT02286687
View directory record Official record
Conditions
Advanced Malignant Neoplasm, ATM Gene Mutation, BRCA1 Gene Mutation, BRCA2 Gene Mutation, Metastatic Malignant Neoplasm, PALB2 Gene Mutation, Recurrent Malignant Neoplasm, Refractory Malignant Neoplasm
Interventions
Laboratory Biomarker Analysis, Pharmacological Study, Talazoparib
Other · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Jul 22, 2026, 5:57 AM EDT
Completed No phase listed Observational

Adherence to Intensive Surveillance for Hereditary Breast Cancer

NCT00582803
View directory record Official record
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
25 Years and older · Female only
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 9, 2009 · Synced Jul 22, 2026, 5:57 AM EDT
Terminated Phase 3 Interventional Results available

A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients

NCT01905592
View directory record Official record
Conditions
Neoplasms, Breast, Carcinoma of Breast, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, BRCA1 Gene Mutation, BRCA2 Gene Mutation, Ovarian Neoplasms
Interventions
niraparib, Physician's choice
Drug
Lead sponsor
Tesaro, Inc.
Industry
Eligibility
18 Years and older
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
25
States / cities
Tucson, Arizona • Los Angeles, California • Fort Myers, Florida + 20 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2022 · Synced Jul 22, 2026, 5:57 AM EDT
Terminated Phase 2 Interventional Results available

Talazoparib For Neoadjuvant Treatment Of Germline BRCA1/2 Mutation Patients With Early Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer

NCT03499353
View directory record Official record
Conditions
Early Breast Cancer
Interventions
TALAZOPARIB
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
97
States / cities
Gilbert, Arizona • Fayetteville, Arkansas • Rogers, Arkansas + 64 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2021 · Synced Jul 22, 2026, 5:57 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Multifactorial Risk Assessment for Breast & Ovarian Cancer Risk Detection

NCT04668521
View directory record Official record
Conditions
Adnexal Mass, Germline BRCA1 Gene Mutation, Germline BRCA2 Gene Mutation, Hereditary Breast and Ovarian Cancer
Interventions
OVA360
Other
Lead sponsor
Aspira Women's Health
Industry
Eligibility
18 Years and older · Female only
Enrollment
215 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Dec 25, 2023 · Synced Jul 22, 2026, 5:57 AM EDT
Completed Phase 2 Interventional Results available

Veliparib in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

NCT01540565
View directory record Official record
Conditions
BRCA1 Mutation Carrier, BRCA2 Mutation Carrier, Ovarian Epithelial Tumor, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
Interventions
Laboratory Biomarker Analysis, Veliparib
Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
153
States / cities
Phoenix, Arizona • Concord, California • La Jolla, California + 114 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2019 · Synced Jul 22, 2026, 5:57 AM EDT
Recruiting Phase 1 Interventional

Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation

NCT04890613
View directory record Official record
Conditions
Advanced Solid Tumor
Interventions
CX-5461
Drug
Lead sponsor
Senhwa Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
6
States / cities
Santa Monica, California • Tampa, Florida • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2026 · Synced Jul 22, 2026, 5:57 AM EDT
Terminated Phase 2 Interventional Results available

BMN 673 (Talazoparib), an Oral PARP Inhibitor, in People With Deleterious BRCA1/2 Mutation-Associated Ovarian Cancer Who Have Had Prior PARP Inhibitor Treatment

NCT02326844
View directory record Official record
Conditions
Ovarian Cancer
Interventions
BMN 673 (talazoparib)
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 99 Years · Female only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 17, 2020 · Synced Jul 22, 2026, 5:57 AM EDT
Recruiting Phase 2 Interventional

Carboplatin Chemotherapy Before Surgery for People With High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene Mutation

NCT05806515
View directory record Official record
Conditions
Prostate Adenocarcinoma, Stage IIIB Prostate Cancer AJCC v8, Stage IIIC Prostate Cancer AJCC v8
Interventions
Biospecimen Collection, Carboplatin, Chest Radiography, Computed Tomography, Magnetic Resonance Imaging, PSMA PET Scan, Surgical Procedure
Procedure · Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older · Male only
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
133
States / cities
Anchorage, Alaska • Phoenix, Arizona • Arroyo Grande, California + 96 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Jul 22, 2026, 5:57 AM EDT
Terminated Phase 2 Interventional Results available

A Phase 2, 2-Stage, 2-Cohort Study of Talazoparib (BMN 673), in Locally Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (ABRAZO Study)

NCT02034916
View directory record Official record
Conditions
Breast Neoplasms, BRCA 1 Gene Mutation, BRCA 2 Gene Mutation
Interventions
talazoparib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
37
States / cities
Greenbrae, California • Los Angeles, California • Palo Alto, California + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2019 · Synced Jul 22, 2026, 5:57 AM EDT
Completed Phase 1 Interventional

A Study of ART4215 for the Treatment of Advanced or Metastatic Solid Tumors

NCT04991480
View directory record Official record
Conditions
Advanced Cancer, Metastatic Cancer, Breast Cancer
Interventions
ART4215, Talazoparib, Niraparib
Drug
Lead sponsor
Artios Pharma Ltd
Industry
Eligibility
18 Years and older
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
7
States / cities
New Haven, Connecticut • Orlando, Florida • New York, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Jul 22, 2026, 5:57 AM EDT
Terminated Phase 2 Interventional Results available

A Study to Evaluate Rucaparib in Participants With Solid Tumors and With Deleterious Mutations in HRR Genes

NCT04171700
View directory record Official record
Conditions
Solid Tumor
Interventions
Rucaparib
Drug
Lead sponsor
pharmaand GmbH
Industry
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
19
States / cities
Los Angeles, California • San Francisco, California • Fort Myers, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2023 · Synced Jul 22, 2026, 5:57 AM EDT
Active, not recruiting Phase 2 Interventional

Olaparib In Metastatic Breast Cancer

NCT03344965
View directory record Official record
Conditions
Metastatic Breast Cancer, Invasive Breast Cancer, Somatic Mutation Breast Cancer (BRCA1), Somatic Mutation Breast Cancer (BRCA2), CHEK2 Gene Mutation, ATM Gene Mutation, PALB2 Gene Mutation, RAD51 Gene Mutation, BRIP1 Gene Mutation, NBN Gene Mutation
Interventions
Olaparib
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
20
States / cities
Birmingham, Alabama • San Francisco, California • Chicago, Illinois + 15 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2026 · Synced Jul 22, 2026, 5:57 AM EDT
Recruiting Phase 3 Interventional

The Cancer of the Pancreas Screening-5 CAPS5)Study

NCT02000089
View directory record Official record
Conditions
Pancreas Cancer, Peutz-Jeghers Syndrome (PJS), Gene Mutation, Germline Mutation Carrier, Lynch Syndrome
Interventions
Secretin, MRI, Tumor marker gene test with CA19-9
Drug · Diagnostic Test · Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
9,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2029
U.S. locations
9
States / cities
New Haven, Connecticut • Baltimore, Maryland • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2025 · Synced Jul 22, 2026, 5:57 AM EDT
Recruiting Phase 2 Interventional

Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer

NCT04090567
View directory record Official record
Conditions
Advanced Breast Carcinoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Germline BRCA1 Gene Mutation, Germline BRCA2 Gene Mutation, HER2/Neu Negative, Metastatic Breast Carcinoma, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage IV Breast Cancer AJCC v8
Interventions
Cediranib, Ceralasertib, Olaparib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Jul 22, 2026, 5:57 AM EDT
Completed Phase 3 Interventional Results available

Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations.

NCT02000622
View directory record Official record
Conditions
Breast Cancer Metastatic, BRCA 1 Gene Mutation, BRCA 2 Gene Mutation
Interventions
Olaparib, Physician's choice chemotherapy
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 99 Years
Enrollment
302 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2025
U.S. locations
42
States / cities
San Diego, California • Santa Rosa, California • Whittier, California + 35 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Jul 22, 2026, 5:57 AM EDT
Completed Phase 3 Interventional Results available

Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments

NCT02282020
View directory record Official record
Conditions
Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity
Interventions
OLAPARIB, Single agent chemotherapy
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years · Female only
Enrollment
266 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
22
States / cities
Birmingham, Alabama • Mobile, Alabama • Sacramento, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2022 · Synced Jul 22, 2026, 5:57 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of Oral Rucaparib in Patients With a Solid Tumor (Phase I) or With gBRCA Mutation Ovarian Cancer (Phase II)

NCT01482715
View directory record Official record
Conditions
Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer, Advanced Solid Tumor With Evidence of Germline or Somatic BRCA
Interventions
Rucaparib
Drug
Lead sponsor
pharmaand GmbH
Industry
Eligibility
18 Years and older · Female only
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
6
States / cities
San Francisco, California • Sarasota, Florida • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2023 · Synced Jul 22, 2026, 5:57 AM EDT
Completed Phase 3 Interventional Results available

A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study)

NCT01945775
View directory record Official record
Conditions
Breast Neoplasms, BRCA 1 Gene Mutation, BRCA 2 Gene Mutation
Interventions
talazoparib, Physician's-Choice
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
431 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
207
States / cities
Flagstaff, Arizona • Scottsdale, Arizona • Antioch, California + 136 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2022 · Synced Jul 22, 2026, 5:57 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Prospective Evaluation of High Resolution Dual Energy Computed Tomographic Imaging, Noninvasive (Liquid) Biopsies, and Minimally Invasive Surgical Surveillance for Early Detection of Mesotheliomas in Patients With BAP1 Tumor Predisposition Syndrome

NCT04431024
View directory record Official record
Conditions
Familial Cancer, BRCA1-Associated Protein-1 (BAP1) Mutations, Tumor Predisposition Syndrome (TPDS), Mesothelioma
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
30 Years to 120 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2038
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Jul 22, 2026, 5:57 AM EDT
Completed Phase 2 Interventional Results available

Cisplatin vs. Doxorubicin/Cyclophosphamide in BrCa

NCT01670500
View directory record Official record
Conditions
Breast Cancer
Interventions
Cisplatin, Cyclophosphamide, Doxorubicin
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2025
U.S. locations
15
States / cities
Aurora, Colorado • Derby, Connecticut • Guilford, Connecticut + 9 more
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Jul 22, 2026, 5:57 AM EDT
Active, not recruiting Phase 2 Interventional

Niraparib + Dostarlimab In BRCA Mutated Breast Cancer

NCT04584255
View directory record Official record
Conditions
Stage I Breast Cancer, Stage II Breast Cancer, Stage III Breast Cancer, Breast Cancer, HER2-negative Breast Cancer, Germline BRCA1 Gene Mutation, Germline BRCA2 Gene Mutation, Deleterious PALB2 Gene Mutation
Interventions
Niraparib, Dostarlimab
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
8
States / cities
New Haven, Connecticut • Baltimore, Maryland • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Jul 22, 2026, 5:57 AM EDT